Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic bone marrow-derived mesenchymal stromal cell therapy - Orbsen Therapeutics

Next Previous
Drug Profile

Allogeneic bone marrow-derived mesenchymal stromal cell therapy - Orbsen Therapeutics

Alternative Names: NEPHSTROM ORBCEL-M; ORBCEL-M; REDDSTAR ORBCEL-M

Latest Information Update: 14 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orbsen Therapeutics
  • Developer Mario Negri Institute for Pharmacological Research; Orbsen Therapeutics
  • Class Mesenchymal stem cell therapies; Stem cell therapies; Uroprotectives
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diabetic nephropathies
  • Phase I Diabetic foot ulcer

Most Recent Events

  • 26 Nov 2024 Orbsen Therapeutics in collaboration with Mario Negri Institute for Pharmacological Research terminates the phase I/II trial in Diabetic nephropathies in United Kingdom, Italya and Ireland (IV) (NCT02585622)
  • 24 Jul 2023 Allogeneic bone marrow-derived mesenchymal stromal cell therapy is still in phase Ib trials for Diabetic foot ulcer in Denmark (Topical) (EudraCT2015-005580-16) (Orbsen Therapeutics pipeline, July 2023)
  • 26 Jan 2023 Orbsen Therapeutics plans a adaptive phase IIb trial for patients with Diabetic nephropathies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top